M&A / Deals Halozyme and Vertex sign deal for Hypercon technology Pharmaceutical Business ReviewVertex has licensed the technology for use in up to three drug targets, as part of the agreement.M&A / DealsRead full story pharminent April 8, 2026 (Last updated: April 8, 2026) Pharmaceutical Business Review Vertex has licensed the technology for use in up to three drug targets, as part of the agreement. M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Gilead continues M&A surge with $3.1B deal for ADC specialist TubulisNext: RoosterBio and MineBio team up to expand MSC solutions access in China Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
